Carisma Therapeutics Inc.(Nasdaq: CARM) (“Carisma” or the “Company”), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief Scientific Officer, will participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:30 am ET.
https://mma.prnewswire.com/media/1219543/Carisma_Therapeutics_Logo.jpg
An audio webcast of the event will be available on the Company'sInvestor Eventssection of the Investor Relations webpage and will be archived for a limited time following the event.
About Carisma
Carisma Therapeutics is a biopharmaceutical Company pioneering macrophage engineering to develop groundbreaking therapies for fibrosis, cancer, and other diseases. With a strong commitment to patient-centric innovation, Carisma aims to deliver scalable, next-generation solutions that transform treatment paradigms. Carisma is headquartered inPhiladelphia, PA.For more information, please visitwww.Carismatx.com.
Investors:Shveta Digheinvestors@carismatx.com
Media Contact:Julia Stern(763) 350-5223jstern@realchemistry.com
https://c212.net/c/img/favicon.png?sn=PH21921&sd=2025-02-19
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-hc-wainwright-3rd-annual-cell-therapy-virtual-conference-302379463.html
SOURCE Carisma Therapeutics Inc.
https://rt.newswire.ca/rt.gif?NewsItemId=PH21921&Transmission_Id=202502190730PR_NEWS_USPR_____PH21921&DateId=20250219